Novo Nordisk Expands Research Collaboration in Novel Delivery Technologies for Biologic Medicines

Novo Nordisk will expand its existing research collaboration in novel delivery technologies with MIT and Brigham and Women’s Hospital.

Novo Nordisk announced on March 9, 2022 that it is expanding its existing research collaboration with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH) focused in oral drug delivery technologies.

Novel technologies have been explored as alternatives to syringes and pen injectors by scientists from Novo Nordisk and the laboratories of Prof. Giovanni Traverso and Prof. Robert Langer since 2015. The collaboration has explored new devices that safely and effectively deliver biologic medicines through oral administration.

The collaboration has been extended through 2026 and will expand its focus to include the creation and integration of bioelectronics, biosensors, and stimuli-responsive delivery devices.

“We continue to explore the immense potential for enhanced delivery of biologic drugs and stem cell-derived therapeutics through the platforms we are developing,” said Giovanni Traverso, the Karl van Tassel, career development assistant professor of mechanical engineering at MIT and a gastroenterologist at Brigham and Women’s Hospital, Harvard Medical School.

Source: Novo Nordisk